Story perspectives

Trump Issues Final Rule for Medicare GLOBE Drug Pilot

By Drooid · Oct 1, 2026, 10:45 AM UTC · How we work

Center

Industry warns price hikes

The U.S. administration issued a final rule creating the GLOBE pilot to lower Medicare prices for office-administered drugs.
President Donald Trump mailed letters to 17 major pharmaceutical firms urging them to match U.S. prices to those in 19 reference nations.
The pilot covers only four manufacturers and excludes companies already holding voluntary MFN agreements.
Canadian industry groups warn the policy may raise prices, cut discounts, or delay new medicines.

Left

Democrats demand repayment

The Trump administration issued a rule creating the GLOBE pilot to lower Medicare prices for office-administered drugs.
Senate Democrats demand Treasury Secretary Scott Bessent repay nearly $1 million in avoided Medicare payroll taxes, calling his conduct a stark example of tax inequity.
An appellate ruling narrowed the limited-partner exemption hedge-fund managers used to dodge taxes.
Senator Ron Wyden warned Bessent’s unpaid taxes damage Medicare’s trust fund and illustrate tax inequity.

Blindspot

Senate Democrats are pressing Treasury Secretary Scott Bessent to repay almost $1 million in Medicare payroll taxes he avoided as a hedge-fund manager, referencing a recent appellate ruling that narrowed the limited-partner exemption used by such managers.
Within this story's sources, this angle appears mainly in Left-leaning coverage and receives less attention in Center-leaning coverage.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act, signed by President Bill Clinton in 2003, created Part D and barred Medicare from negotiating drug prices, projecting roughly $400 billion in costs over the next decade. As spending rose, CMS pursued cost-containment, and the Trump administration’s GLOBE pilot now echoes the 2003 model, urging manufacturers to match prices while Secretary Scott Bessent returns $1 million in payroll taxes.

1 of 4

Industry warns price hikes

The U.S. administration issued a final rule creating the GLOBE pilot to lower Medicare prices for office-administered drugs.
President Donald Trump mailed letters to 17 major pharmaceutical firms urging them to match U.S. prices to those in 19 reference nations.
The pilot covers only four manufacturers and excludes companies already holding voluntary MFN agreements.
Canadian industry groups warn the policy may raise prices, cut discounts, or delay new medicines.

1 / 4